Literature DB >> 19223557

Conserved gene expression programs integrate mammalian prostate development and tumorigenesis.

Colin Pritchard1, Brig Mecham, Ruth Dumpit, Ilsa Coleman, Madhuchhanda Bhattacharjee, Qian Chen, Robert A Sikes, Peter S Nelson.   

Abstract

Studies centered at the intersection of embryogenesis and carcinogenesis have identified striking parallels involving signaling pathways that modulate both developmental and neoplastic processes. In the prostate, reciprocal interactions between epithelium and stroma are known to influence neoplasia and also exert morphogenic effects via the urogenital sinus mesenchyme. In this study, we sought to determine molecular relationships between aspects of normal prostate development and prostate carcinogenesis. We first characterized the gene expression program associated with key points of murine prostate organogenesis spanning the initial in utero induction of prostate budding through maturity. We identified a highly reproducible temporal program of gene expression that partitioned according to the broad developmental stages of prostate induction, branching morphogenesis, and secretory differentiation. Comparisons of gene expression profiles of murine prostate cancers arising in the context of genetically engineered alterations in the Pten tumor suppressor and Myc oncogene identified significant associations between the profile of branching morphogenesis and both cancer models. Further, the expression of genes comprising the branching morphogenesis program, such as PRDX4, SLC43A1, and DNMT3A, was significantly altered in human neoplastic prostate epithelium. These results indicate that components of normal developmental processes are active in prostate neoplasia and provide further rationale for exploiting molecular features of organogenesis to understand cancer phenotypes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19223557     DOI: 10.1158/0008-5472.CAN-07-6817

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  40 in total

1.  Atlas of Wnt and R-spondin gene expression in the developing male mouse lower urogenital tract.

Authors:  Vatsal Mehta; Lisa L Abler; Kimberly P Keil; Christopher T Schmitz; Pinak S Joshi; Chad M Vezina
Journal:  Dev Dyn       Date:  2011-09-20       Impact factor: 3.780

2.  Androgen-Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression.

Authors:  Paula J Hurley; Robert M Hughes; Brian W Simons; Jessie Huang; Rebecca M Miller; Brian Shinder; Michael C Haffner; David Esopi; Yasunori Kimura; Javaneh Jabbari; Ashley E Ross; Nicholas Erho; Ismael A Vergara; Sheila F Faraj; Elai Davicioni; George J Netto; Srinivasan Yegnasubramanian; Steven S An; Edward M Schaeffer
Journal:  Cancer Res       Date:  2015-08-20       Impact factor: 12.701

3.  Differential expression of peroxiredoxins in prostate cancer: consistent upregulation of PRDX3 and PRDX4.

Authors:  Anamika Basu; Hiya Banerjee; Heather Rojas; Shannalee R Martinez; Sourav Roy; Zhenyu Jia; Michael B Lilly; Marino De León; Carlos A Casiano
Journal:  Prostate       Date:  2010-10-28       Impact factor: 4.104

4.  PI3K/mTOR signaling regulates prostatic branching morphogenesis.

Authors:  Susmita Ghosh; Hiu Lau; Brian W Simons; Jonathan D Powell; David J Meyers; Angelo M De Marzo; David M Berman; Tamara L Lotan
Journal:  Dev Biol       Date:  2011-10-08       Impact factor: 3.582

5.  Reactivation of embryonic nodal signaling is associated with tumor progression and promotes the growth of prostate cancer cells.

Authors:  Mitchell G Lawrence; Naira V Margaryan; Daniela Loessner; Angus Collins; Kris M Kerr; Megan Turner; Elisabeth A Seftor; Carson R Stephens; John Lai; Lynne-Marie Postovit; Judith A Clements; Mary J C Hendrix
Journal:  Prostate       Date:  2011-01-12       Impact factor: 4.104

Review 6.  The sulfiredoxin-peroxiredoxin (Srx-Prx) axis in cell signal transduction and cancer development.

Authors:  Murli Mishra; Hong Jiang; Lisha Wu; Hedy A Chawsheen; Qiou Wei
Journal:  Cancer Lett       Date:  2015-07-10       Impact factor: 8.679

Review 7.  Prostate organogenesis: tissue induction, hormonal regulation and cell type specification.

Authors:  Roxanne Toivanen; Michael M Shen
Journal:  Development       Date:  2017-04-15       Impact factor: 6.868

8.  The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis.

Authors:  Jared M Lucas; Cynthia Heinlein; Tom Kim; Susana A Hernandez; Muzdah S Malik; Lawrence D True; Colm Morrissey; Eva Corey; Bruce Montgomery; Elahe Mostaghel; Nigel Clegg; Ilsa Coleman; Christopher M Brown; Eric L Schneider; Charles Craik; Julian A Simon; Antonio Bedalov; Peter S Nelson
Journal:  Cancer Discov       Date:  2014-08-13       Impact factor: 39.397

Review 9.  Follistatin as potential therapeutic target in prostate cancer.

Authors:  Maria Vittoria Sepporta; Francesca Maria Tumminello; Carla Flandina; Marilena Crescimanno; Marco Giammanco; Maurizio La Guardia; Danila di Majo; Gaetano Leto
Journal:  Target Oncol       Date:  2013-03-01       Impact factor: 4.493

10.  MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells.

Authors:  Tsuyoshi Iwata; Denise Schultz; Jessica Hicks; Gretchen K Hubbard; Laura N Mutton; Tamara L Lotan; Carlise Bethel; Matthew T Lotz; Srinivasan Yegnasubramanian; William G Nelson; Chi V Dang; MengMeng Xu; Uzoma Anele; Cheryl M Koh; Charles J Bieberich; Angelo M De Marzo
Journal:  PLoS One       Date:  2010-02-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.